Skip to content

pierrot harvie

  • Ph.D.
  • Associate Director of Formulation
  • PhaseRx Inc
  • 15h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 907CitationsNumber of citations received by pierrot's publications. Updated daily.

Other IDs

Research interests

polymer peptideliposomesdeliverysiRNA

About

• More than Ten years experience working with drug delivery systems. • Expertise in delivering siRNA, miRNA, plasmid DNA and small molecules with liposomes and nanoparticles • Expertise with lipid, polymer, peptide, poly-cation, and pH sensitive polymer as drug delivery system. • Strong technical knowledge and practical skills in most of the biophysical, biological as well as the molecular biology techniques generally used to characterize drug and gene delivery systems. • Solid background in preclinical pharmacology and toxicity, and experience in the evaluation of drug delivery systems for anti-tumor activity. • Experience with process development technique and knowledge of GMP manufacturing regulation. • Proficient in most of the virological, and immunological techniques and experience in histopathology analysis, with respect to disease progression to evaluate drug efficacy or toxicity.

Co-authors (84)

Publications (5)

  • Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency

    • Prieve M
    • Harvie P
    • Monahan S
    • et al.
    N/AReaders
    1Citations
    Get full text
  • An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA

    • Adami R
    • Seth S
    • Harvie P
    • et al.
    N/AReaders
    35Citations
    Get full text
  • Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs

    • Vaish N
    • Chen F
    • Seth S
    • et al.
    N/AReaders
    52Citations
    Get full text
  • RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

    • Seth S
    • Matsui Y
    • Fosnaugh K
    • et al.
    N/AReaders
    42Citations
    Get full text
  • Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model

    • Harvie P
    • Omar R
    • Dusserre N
    • et al.
    N/AReaders
    14Citations
    Get full text

Professional experience

Associate Director of Formulation

PhaseRX

March 2013 - Present

Sr Research Scientist

Marina biotech (Formerly MDRNA inc)

January 2007 - July 2012(6 years)

Scientist

Celator pharmaceutical

July 2003 - October 2006(3 years)

Scientsit

Targeted Genetics Corporation

November 1999 - February 2003(3 years)

Education

Ph.D.

Université Laval - Laval University

September 1993 - May 1996(3 years)